New HIV vaccine candidate enters early safety testing
NCT ID NCT05423418
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental HIV vaccine in 65 healthy adults to see if it is safe and triggers an immune response. The vaccine includes two HIV proteins (A244 and B.63521) plus an adjuvant (ALFQ) to boost the immune system. Participants received three shots over two months, with different doses of the adjuvant to find the best balance of safety and immune reaction.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HIV vaccine (A244 and B.63521 proteins) with ALFQ adjuvant
What this could lead to
If successful, this could help determine the best dose of ALFQ adjuvant for an HIV vaccine, moving us closer to an effective preventive shot.
What could go wrong
This is an early phase 1 trial with only 65 healthy, low-risk participants. It focuses on safety and immune response, not on preventing HIV infection. The vaccine may not produce strong enough immunity or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS (HIV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Walter Reed Army Institute of Research, Clinical Trials Center
Silver Spring, Maryland, 20910, United States